Associate Director - Event Planning
About the job
- The candidate must have 7 or more years of event planning experience, including significant experience in the biotechnology or pharmaceutical industry or at a corporate agency supporting biopharmaceutical clients, with demonstrated experience leading complex internal events and major congresses.
- The candidate must have experience managing the logistics and execution of major events in the United States and internationally.
- The candidate must have biopharmaceutical or pharmaceutical commercial event experience and a strong understanding of the healthcare and convention environment.
- The candidate must have strategic thinking, project management, communication, negotiation, and stakeholder-management skills, with the ability to lead and influence cross-functional teams in a highly matrixed environment.
- The candidate must be able to manage multiple complex events, projects, timelines, and budgets simultaneously while maintaining attention to detail and execution quality.
- The candidate must be able to identify industry trends, simplify processes, improve efficiency, and introduce innovative ways of working.
- The candidate must be able to establish and maintain productive partnerships with internal stakeholders, external vendors, and industry partners.
- The candidate must understand the broader business context and connect event strategy and execution to commercial priorities and stakeholder needs.
- The candidate must be proficient with Microsoft Office, Cvent, and Smartsheet and demonstrate interest in leveraging technology and digital tools to improve event-planning efficiency, transparency, and stakeholder experience.
- A bachelor's degree is required.
- Own and lead the end-to-end planning and execution of assigned Commercial Events, including project plans, timelines, action plans, communication strategies, and deliverables.
- Partner with Commercial and Medical business leads to align event strategy and execution with brand and business plans.
- Lead planning for priority Tier 1 and Tier 2 Congresses, including housing, registration, exhibit and meeting space, ancillary meetings, sponsorships, advertising opportunities, related technologies, medical education activities, pre-event planning, and onsite execution.
- Provide hands-on logistics support for internal and smaller Commercial Events, including department offsites, headquarters events, and business meetings that do not require dedicated vendor support.
- Provide onsite leadership for assigned events, including pre-event setup and real-time issue resolution; weekend support may be required.
- Facilitate cross-functional planning meetings and ensure stakeholders and external partners are aligned on objectives, responsibilities, timelines, and deliverables.
- Build and maintain relationships with external logistics and event vendors and oversee their delivery against agreed-upon scope, timelines, and expectations.
- Provide proactive communication to internal stakeholders and external partners throughout the event lifecycle.
- Evaluate and prioritize the congress calendar to ensure appropriate representation across priority specialty areas in rare disease.
- Serve as the business owner for the commercial field exhibits and sponsorships process, including standards, governance, execution, reporting, and continuous improvement.
- Manage event budgets and financial processes, including vendor estimates, statements of work and contracts, purchase orders, invoice approvals, reconciliation, and cross-charges.
- Partner with Legal, Compliance, Finance, Procurement, and Commercial Contracting to ensure contracts, payments, and event activities are completed accurately and on time.
- Ensure assigned events comply with applicable healthcare professional, legal, regulatory, and company requirements.
- Evaluate commercial event effectiveness and identify opportunities to improve efficiency, consistency, stakeholder experience, and overall event impact.
- Develop and implement solutions, technologies, policies, processes, and best practices that simplify and improve event planning and execution.
- Produce pre-event communications and post-event reporting, including key metrics, surveys, debriefs, and budget reconciliation.
- Travel up to 50%, primarily domestically with some international travel, for pre-event setup, onsite event execution, and issue resolution.
- Prior people-management experience leading, coaching, and developing event-planning professionals, including setting priorities, delegating effectively, providing performance feedback, and building a high-performing team, is strongly preferred.
- Certified Trade Show Marketer certification or Certified Meeting Professional certification is a plus.
About the company
Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.
Company Size
201-500
Company Stage
IPO
Headquarters
Foster City, California
Founded
2018
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- ATEBRIOZ won FDA approval on September 25, 2026, creating a new commercial launch.
- Second-quarter 2026 revenue reached $176.2 million, and management raised 2026 guidance to $680-$700 million.
- Brelovitug hit its Phase 3 AZURE-1 endpoint on September 28, 2026, strengthening launch odds.
What critics are saying
- FDA told Mirum to run another Phase 3 for volixibat, pushing PSC filing to H1 2027.
- Brelovitug still needs AZURE-4 in Q4 2026 before a H1 2027 BLA submission.
- A failure in LIVMARLI, brelovitug, or ATEBRIOZ would leave Mirum heavily concentrated.
What makes Mirum Pharmaceuticals unique
- Mirum now has three late-stage programs: LIVMARLI, brelovitug, and ATEBRIOZ.
- LIVMARLI keeps expanding across pediatric cholestatic diseases, reinforcing a rare-liver-disease franchise.
- Brelovitug targets chronic hepatitis delta with no approved U.S. competitor.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
1%1 year growth
1%2 year growth
0%Mirum's liver infection drug lowers virus levels in late-stage study. By Thomson Reuters Sep 28, 2026 | 8:49 AM By Sneha S K Sept 28 (Reuters) - Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study. Here are some key details: - Mirum was testing brelovitug, an experimental monoclonal antibody that binds to the hepatitis B surface antigen, a protein found on the surface of the virus - The company was testing the treatment for chronic hepatitis delta virus, a liver infection that affects people already infected with hepatitis B - The disease, which the company estimates affects about 230,000 people in the US and Europe, can cause severe symptoms that can lead to liver damage and, in some cases, death - At 24 weeks, 56% of patients given 300 milligrams of brelovitug and 45% of those given 900 milligrams showed reduced hepatitis D virus levels and normal liver enzyme levels, compared with 0% in the delayed-treatment group, the company said - The company expects the drug to generate peak sales of at least $1 billion - The only FDA-approved treatment for the condition is Gilead's Hepcludex - "Brelovitug has a better benefit/risk profile," said RBC Capital Markets analyst Lisa Walter, adding that the latest results position it as the best-in-class treatment option - The drug was well tolerated across dose groups, with a safety profile consistent with previously reported data, Mirum said - Full results from the study will be presented at an upcoming medical congress, with the company expecting to submit a marketing application for the drug to the US FDA in the first half of 2027. (Reporting by Sneha S K in Bengaluru; Editing by Jonathan Ananda and Diti Pujara)
The US Food and Drug Administration has approved Atebrioz (zilurgisertib) for adult and paediatric patients aged 12 and older with fibrodysplasia ossificans progressiva, a rare genetic disease affecting approximately 300 people in the United States. Mirum Pharmaceuticals and Incyte announced the approval, which makes Atebrioz the latest treatment option for the progressive condition that causes bone to form in muscles, tendons, and other soft tissues. The once-daily oral tablet works by inhibiting ALK2, targeting the disease-driving pathway. Clinical trial data showed that at 24 weeks, mean total new heterotopic ossification volume decreased by 3.2 cm³ in patients receiving the drug compared with an increase of 24.6 cm³ in placebo-treated patients. Atebrioz is expected to be commercially available in October through Mirum Access Plus, with eligible patients paying as little as $0 per month.
U.S. FDA approves Mirum Pharmaceuticals' zilurgisertib as a treatment for FOP. Posted on September 25, 2026 Atebrioz(TM) is the third treatment approved for people living with FOP in the United States. Today, September 25, is an incredible day for the FOP community! IFOPA want to start by thanking FOP community members from around the world who participated in the zilurgisertib trial. Mirum Pharmaceuticals and Incyte have announced the U.S. Food & Drug Administration's (FDA) approval of zilurgisertib tablets for the treatment of fibrodysplasia ossificans progressiva (FOP) in the United States. Zilurgisertib is the first FOP drug approved after completing only a Phase 2 clinical trial. * The brand name of the drug is Atebrioz(TM) * Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP. * Mirum will soon release websites to help people with FOP and their local healthcare providers learn more about Atebrioz. * Atebrioz is expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month. * Atebrioz is only available for treatment of FOP for individuals in the United States. * The European Medicines Agency (EMA) in the European Union is also reviewing zilurgisertib. Letter from Mirum's CEO. Thank you. Zilurgisertib (now known as Atebrioz) was tested in the PROGRESS Phase 2 clinical trial. IFOPA is deeply grateful to the 63 people with FOP who participated. IFOPA is also grateful to the Principal Investigators, Study Coordinators, and all of the staff at the trial sites who took such good care of its families. IFOPA want to thank Novartis, Incyte, and Mirum for their commitment and dedication to the FOP community. Publications & Presentations. The links below include press releases, a poster, and a plain language summary of the PROGRESS trial results. IFOPA expect a publication in a peer-reviewed journal. Presentations from the 2026 7th FOP Drug Development Forum Incyte shared this poster and plain-language summary of their results, which show an 81% reduction in the proportion of patients with new lesions at Week 24 (compared to placebo), at ENDO 2026, the leading global meeting on endocrinology research and clinical care hosted by the Endocrine Society. Where is Atebrioz approved? It is important to note that the FDA's approval of Atebrioz is only for people aged 12 and older with FOP living in the United States. On August 5, 2026, Mirum announced during an Investor Call that the EMA in the European Union accepted zilurgisertib for review. IFOPA await the EMA's decision. In what other countries is Mirum seeking approval of zilurgisertib? Zilurgisertib previously received Fast Track designation and Orphan Drug Designation from the FDA, as well as Orphan Designation by the European Medicines Agency in the European Union. IFOPA communicate regularly with Mirum about developments with zilurgisertib and will share announcements with the FOP community when they are publicly available. Is zilurgisertib in a trial for children younger than 12? The PROGRESS Phase 2 trial includes an active Cohort 2 for children ages 6 to < 12 years of age that is fully enrolled. Cohort 3 for children ages 2 to < 12 years is recruiting. You can learn more at ifopa.org/progress If you would like to receive updates on clinical trials and drug reviews, please sign up for IFOPA's Clinical Trial Alerts at ifopa.org/clinical-trial-alerts About zilurgisertib. People with FOP harbor mutations in the ALK2 protein (also known as ACVR1) that drives excessive bone morphogenetic protein (BMP) signaling, which regulates cartilage and bone development. Zilurgisertib (INCB000928) is an oral investigational drug designed to target and block this disease-causing mutant FOP protein hyperactivity. In preclinical studies, zilurgisertib demonstrated potency for the target kinase, selectivity, safety and strong suppression of heterotopic ossification (HO) in animal models.
Mirum Pharmaceuticals has appointed Dr Rob Myers as chief medical officer, effective 21 September 2026. Dr Myers will lead the company's global medical and clinical development functions. Dr Myers brings over 20 years of experience in drug development, with particular expertise in hepatology. He joins from OrsoBio, where he served as chief medical officer and head of development. Previously, he held senior leadership positions at Gilead Sciences, overseeing clinical development programmes across liver fibrosis, cholestatic liver diseases, and gastrointestinal inflammation. Dr Myers has published more than 200 peer-reviewed papers and has contributed to advancing understanding of primary sclerosing cholangitis. He holds an MD from Western University and a master's degree in epidemiology from the University of Calgary.
US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.